US
English
Search
The 2014 amendment to the FDA’s regulations governing the content and format of labeling for human prescription drugs and biological products also requires the inclusion of a “Females and Males of Reproductive Potential” subsection.2,3 The subsection provides guidance when pregnancy testing or contraception is required or recommended before, during, or after drug therapy; or when there are human or animal data that suggest drug-associated fertility effects.
Your session is about to expire. Do you want to continue logged in?
